0001933567
false
0001933567
2023-09-21
2023-09-21
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF
THE
SECURITIES EXCHANGE ACT OF 1934
Date
of Report (Date of earliest event reported): September 21, 2023
Neuraxis,
Inc.
(Exact
name of registrant as specified in its charter)
Delaware |
|
001-41775 |
|
45-5079684 |
(State or other jurisdiction
of incorporation) |
|
(Commission
File Number) |
|
(I.R.S. Employer
Identification No.) |
11550
N. Meridian Street, Suite 325
Carmel,
IN 46032 |
(Address
of principal executive offices) |
Registrant’s
telephone number, including area code: (812) 689-0791
N/A |
(Former
name or former address, if changed since last report) |
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
Common
Stock, $0.001 par value |
|
NRXS |
|
NYSE
American |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☒
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item
2.02 |
Results
of Operations and Financial Condition |
On
September 21, 2023, Neuraxis, Inc. (the “Company”) announced its financial results for the second quarter ended June
30, 2023. A copy of the press release is furnished as Exhibit 99.1 and is incorporated herein by reference.
Item
7.01. |
Regulation
FD Disclosure. |
The
Company also prepared an investor presentation containing certain information and financial highlights about the Company and its industry.
A copy of the presentation materials is attached hereto as Exhibit 99.2 and is incorporated herein by reference.
The
information contained in Item 2.02 and Item 7.01 (including Exhibits 99.1 and 99.2) shall not be deemed to be “filed” for
the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject
to the liabilities of that section, and such information is not incorporated by reference into any registration statements or other document
filed under the Securities Act of 1933, as amended or the Exchange Act, regardless of the general incorporation language contained in
such filing, except as shall be expressly set forth by specific reference to this filing.
Item
9.01. |
Financial
Statements and Exhibits. |
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
Date:
September 21, 2023 |
NEURAXIS,
INC. |
|
|
|
By:
|
/s/
Brian Carrico |
|
Name:
|
Brian
Carrico |
|
Title:
|
President
and Chief Executive Officer |
Exhibit 99.1
NeurAxis
Reports Second Quarter 2023 Financial Results
Carmel,
Ind., September 21, 2023 (GLOBE NEWSWIRE) – NeurAxis, Inc. (NYSE American: NRXS) (“NeurAxis” or the “Company”),
a medical technology company commercializing neuromodulation therapies that address chronic and debilitating conditions in children and
adults, today reported financial results for the second quarter ended June 30, 2023.
Recent
Highlights:
| ● | Announced
a poster presentation titled, “Percutaneous Electrical Nerve Field Stimulation Saves
Cost to Parents and Insurers of Adolescents with Irritable Bowel Syndrome”, from
the University of Michigan at the 2023 American Neurogastroenterology and Motility Society
(ANMS) Annual Meeting, highlighting the cost-effectiveness of its PENFS or IB-Stim™
therapy in the treatment of irritable bowel syndrome in adolescents. Noting: |
| ○ | IB-Stim™
therapy increases the number of healthy days, based on effective treatment of abdominal pain
symptoms, in adolescents suffering from IBS; |
| ○ | Treatment
with IB-Stim™ results in approximately 60% or $4,744 of potential cost-savings to insurers;
and |
| ○ | IB-Stim™
treatment also offers the potential cost-saving opportunity of approximately 53% or $5,802
to patients’ families. |
| ● | Highlighted
two recently published independent studies showing that IB-Stim™ therapy leads to improvements
in abdominal pain and disability in adolescents with IBS and that the gut microbiome may
play an important role. |
| ● | Announced
the publication of Prospective study of the effect of auricular percutaneous electrical
nerve field stimulation on quality of life in children with pain related disorders of gut-brain
interaction, a randomized, double-blind, placebo-controlled trial to evaluate the efficacy
of IB-Stim™ in children with post-concussion symptoms, featured in the September
2023 Frontiers in Pain Research. Noting: |
| ○ | Patients
(n=31) reported significant reductions in abdominal pain, nausea, disability, and anxiety
from baseline to week 4 (p < 0.05); |
| ○ | Parent
assessments reported significant improvement in the child’s quality of life based on
physical function, psychosocial function, and generic core scale scores (p < 0.05); and |
| ○ | Parents
also reported reduced abdominal pain, functional disability, and somatization in their child.
The global health scores also significantly improved based on both patient and parent reports
(p < 0.05). |
| ● | Completed
initial public offering of common stock which raised net proceeds of approximately $6.1 million. |
“We
are thrilled with the progress we have made, especially now as a public company, with funds raised to steadily drive our momentum,”
said Brian Carrico, President and Chief Executive Officer of NeurAxis. “The support we are receiving, including our recently highlighted
10th peer reviewed publication, out of a total 14 publications to-date, demonstrates our continuing commitment to grow our
body of clinical evidence. Further, as we approach our target of 16 publications, we believe the foundation of strong clinical evidence
we have positions us for expanded payor coverage and the adoption of IB-Stim™. We look forward to our continuing progress to grow
our business, in line with our goal to make IB-Stim™ the standard of care for children with abdominal pain related disorders of
the gut-brain interactions.”
Second
Quarter 2023 Financial Results
Revenue
for the second quarter of 2023 was $646.0 thousand, representing a decrease of 5% compared to $682.6 thousand in the second quarter of
2022. The decrease was primarily due to ordering patterns of our major customers.
Gross
profit for the second quarter of 2023 was $578.2 thousand, representing a decrease of 4% compared to a gross profit of $603.6 thousand
in the second quarter of 2022. Gross margin totaled 89.5% in the second quarter of 2023, compared to 88.4% in second quarter of 2022.
The increase was primarily due to slightly lower cost of sales.
Selling
expenses for the second quarter of 2023 were $78.8 thousand, compared to $127.4 thousand in the second quarter of 2022. The decrease
was primarily due to lower commission costs, with the commission rate being lowered at the beginning of 2023.
Second
quarter research and development expenses were $109.8 thousand, compared to $13.7 thousand in the second quarter of 2022, reflecting
increased spend primarily on new product development.
General
and administrative expenses for the second quarter of 2023 were $1,507.2 thousand, compared to $1,132.1 thousand in the second quarter
of 2022. The increase was primarily due to higher professional fees.
Second
quarter net loss was ($2,235.6) thousand, or ($1.21) per common share, compared to ($1,516.5) thousand, or ($0.87) per
common share, for the same period of 2022.
Forward-Looking
Statements
Certain
statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are forward-looking
statements. Forward-looking statements are based on management’s current assumptions and expectations of future events and trends,
which affect or may affect the Company’s business, strategy, operations or financial performance, and actual results and other
events may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking
statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. There are a number of
important factors that could cause actual results, developments, business decisions or other events to differ materially from those contemplated
by the forward-looking statements in this press release. These factors include, among other things, the conditions in the U.S. and global
economy, the trading price and volatility of the Company’s stock, public health issues or other events, the Company’s compliance
with applicable laws, the results of the Company’s clinical trials and perceptions thereof, as well as factors described in the
Risk Factors section of NeurAxis’s public filings with the Securities and Exchange Commission (SEC). Because forward-looking statements
are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events.
These forward-looking statements speak only as of the date of this press release and, except to the extent required by applicable law,
the Company undertakes no obligation to update or revise these statements, whether as a result of any new information, future events
and developments or otherwise.
About
NeurAxis, Inc.
NeurAxis,
Inc., is a medical technology company focused on neuromodulation therapies to address chronic and debilitating conditions in children
and adults. NeurAxis is dedicated to advancing science and leveraging evidence-based medicine to drive adoption of its IB-Stim™
therapy, which is its proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology, by the medical, scientific, and
patient communities. IB-Stim™ is FDA cleared for functional abdominal pain associated with irritable bowel syndrome (IBS) in adolescents
11-18 years old. Additional clinical trials of PENFS in multiple pediatric and adult conditions with large unmet healthcare needs are
underway. For more information, please visit http://neuraxis.com.
Contacts:
Company
NeurAxis,
Inc.
info@neuraxis.com
Investor
Relations
Gilmartin
Group
IR@neuraxis.com
NeurAxis,
Inc.
Condensed
Statements of Operations
(unaudited)
| |
For the Three Months Ended June 30, | | |
For the Six Months Ended June 30, | |
| |
2023 | | |
2022 | | |
2023 | | |
2022 | |
| |
| | |
| | |
| | |
| |
Net Sales | |
$ | 646,021 | | |
$ | 682,581 | | |
$ | 1,451,131 | | |
$ | 1,452,848 | |
Cost of Goods Sold | |
| 67,813 | | |
| 79,009 | | |
| 163,713 | | |
| 154,209 | |
| |
| | | |
| | | |
| | | |
| | |
Gross Profit | |
| 578,208 | | |
| 603,572 | | |
| 1,287,418 | | |
| 1,298,639 | |
| |
| | | |
| | | |
| | | |
| | |
Selling Expenses | |
| 78,791 | | |
| 127,424 | | |
| 186,723 | | |
| 263,304 | |
Research and Development | |
| 109,789 | | |
| 13,665 | | |
| 126,586 | | |
| 58,063 | |
General and Administrative | |
| 1,507,169 | | |
| 1,132,065 | | |
| 2,987,923 | | |
| 2,160,161 | |
| |
| | | |
| | | |
| | | |
| | |
Operating Loss | |
| (1,117,541 | ) | |
| (669,582 | ) | |
| (2,013,814 | ) | |
| (1,182,889 | ) |
| |
| | | |
| | | |
| | | |
| | |
Other Income (Expense): | |
| | | |
| | | |
| | | |
| | |
Financing charges | |
| — | | |
| (872,763 | ) | |
| (2,772 | ) | |
| (872,763 | ) |
Interest expense | |
| (194,690 | ) | |
| (34,450 | ) | |
| (356,378 | ) | |
| (60,550 | ) |
Change in fair value of warrant liability | |
| (36,050 | ) | |
| 61,520 | | |
| 198,757 | | |
| (569,561 | ) |
Change in fair value of derivative liability | |
| 860 | | |
| — | | |
| 192,157 | | |
| — | |
Amortization of debt discount and issuance cost | |
| (887,937 | ) | |
| (12,944 | ) | |
| (3,550,592 | ) | |
| (12,944 | ) |
Extinguishment of debt liabilities | |
| — | | |
| — | | |
| 1,129,498 | | |
| — | |
Other income | |
| 2 | | |
| 11,689 | | |
| 1,552 | | |
| 11,956 | |
Other expense | |
| (258 | ) | |
| — | | |
| (7,430 | ) | |
| — | |
Total other income (expense), net | |
| (1,118,073 | ) | |
| (846,948 | ) | |
| (2,395,208 | ) | |
| (1,503,862 | ) |
| |
| | | |
| | | |
| | | |
| | |
Net Loss | |
$ | (2,235,614 | ) | |
$ | (1,516,530 | ) | |
$ | (4,409,022 | ) | |
$ | (2,686,751 | ) |
| |
| | | |
| | | |
| | | |
| | |
Per-share Data | |
| | | |
| | | |
| | | |
| | |
Basic and diluted loss per share | |
$ | (1.21 | ) | |
$ | (0.87 | ) | |
$ | (2.39 | ) | |
$ | (1.56 | ) |
| |
| | | |
| | | |
| | | |
| | |
Weighted Average Shares Outstanding | |
| | | |
| | | |
| | | |
| | |
Basic and diluted | |
| 2,003,322 | | |
| 1,970,054 | | |
| 2,003,322 | | |
| 1,970,054 | |
NeurAxis,
Inc.
Condensed
Balance Sheet
(unaudited)
| |
June 30, | | |
| |
| |
2023 (Unaudited) | | |
December 31, 2022 | |
Assets | |
| | | |
| | |
Current Assets: | |
| | | |
| | |
Cash and cash equivalents | |
$ | 51,440 | | |
$ | 253,699 | |
Accounts receivable, net | |
| 237,170 | | |
| 174,399 | |
Inventories | |
| 44,205 | | |
| 48,133 | |
Prepaids and other current assets | |
| 21,333 | | |
| 726 | |
Total current assets | |
| 354,148 | | |
| 476,957 | |
| |
| | | |
| | |
Property and Equipment, at cost: | |
| 417,912 | | |
| 405,845 | |
Less - accumulated depreciation | |
| (332,651 | ) | |
| (317,834 | ) |
Property and equipment, net | |
| 85,261 | | |
| 88,011 | |
| |
| | | |
| | |
Other Assets: | |
| | | |
| | |
Deferred offering costs | |
| 941,143 | | |
| 736,736 | |
Operating lease right of use asset | |
| 85,823 | | |
| 101,382 | |
Intangible assets, net | |
| 73,316 | | |
| 77,558 | |
Total Assets | |
$ | 1,539,691 | | |
$ | 1,480,644 | |
| |
| | | |
| | |
Liabilities | |
| | | |
| | |
Current Liabilities: | |
| | | |
| | |
Accounts payable | |
$ | 2,438,117 | | |
$ | 1,592,116 | |
Accrued expenses | |
| 1,174,381 | | |
| 834,062 | |
Notes payable | |
| 249,389 | | |
| 202,834 | |
Current portion of operating lease payable | |
| 41,261 | | |
| 33,395 | |
| |
| | | |
| | |
Notes payable - related party | |
| 58,051 | | |
| 58,051 | |
Notes payable - convertible notes, net of unamortized discount of $4,421,424 and $3,327,213 as of June 30, 2023 and December 31, 2022 | |
| 1,217,465 | | |
| 228,342 | |
Customer deposits | |
| 61,317 | | |
| 59,174 | |
Derivative liabilities | |
| 2,275,029 | | |
| 1,735,700 | |
Warrant liabilities | |
| 3,916,884 | | |
| 2,234,384 | |
Total current liabilities | |
| 11,431,894 | | |
| 6,978,058 | |
| |
| | | |
| | |
Non-current Liabilities: | |
| | | |
| | |
Operating lease payable, net of current portion | |
| 51,635 | | |
| 76,199 | |
Note payable, net of current portion | |
| 38,797 | | |
| — | |
Total non-current liabilities | |
| 90,432 | | |
| 76,199 | |
| |
| | | |
| | |
Total liabilities | |
| 11,522,326 | | |
| 7,054,257 | |
Commitments and contingencies (see note 14) | |
| | | |
| | |
Stockholders’ Deficit | |
| | | |
| | |
| |
| | | |
| | |
Convertible Series A Preferred stock, $0.001 par value; 1,000,000 shares authorized; 506,637 issued and outstanding as of June 30, 2023 and December 31, 2022 | |
| 507 | | |
| 507 | |
Convertible Series Seed Preferred Stock, $0.001 par value; 120,000 shares authorized; 115,477 issued and outstanding as of June 30, 2023 and December 31, 2022 | |
| 115 | | |
| 115 | |
Common stock, $0.001 par value; 100,000,000 shares authorized; 1,963,322 issued and outstanding as of June 30, 2023 and December 31, 2022 | |
| 1,963 | | |
| 1,963 | |
Additional paid in capital | |
| 28,355,230 | | |
| 28,355,230 | |
Accumulated deficit | |
| (38,340,450 | ) | |
| (33,931,428 | ) |
| |
| | | |
| | |
Total stockholders’ deficit | |
| (9,982,635 | ) | |
| (5,573,613 | ) |
| |
| | | |
| | |
Total Liabilities and Stockholders’ Deficit | |
$ | 1,539,691 | | |
$ | 1,480,644 | |
NeurAxis,
Inc.
Condensed
Statement of Cash Flows
(unaudited)
| |
For the Six Months Ended June 30, | |
| |
2023 | | |
2022 | |
Cash Flows from Operating Activities | |
| | | |
| | |
Net Loss | |
$ | (4,409,021 | ) | |
$ | (2,117,190 | ) |
Adjustments to reconcile net loss to net cash used by operating activities: | |
| | | |
| | |
Amortization of debt discount and issuance cost | |
| 3,550,592 | | |
| 12,944 | |
Depreciation and amortization | |
| 20,060 | | |
| 16,695 | |
Provisions for losses on accounts receivable | |
| 3,927 | | |
| 29,580 | |
Non-cash lease expense | |
| 15,559 | | |
| 13,296 | |
Stock based compensation | |
| — | | |
| 24,121 | |
Extinguishment of debt liability | |
| (1,129,498 | ) | |
| — | |
Finance Charges | |
| 2,772 | | |
| 872,763 | |
Change in fair value of derivative liabilities | |
| (192,157 | ) | |
| — | |
Change in fair value of warrant liabilities | |
| (198,757 | ) | |
| 569,563 | |
Changes in operating assets and liabilities: | |
| | | |
| | |
Accounts receivable | |
| (66,698 | ) | |
| (131,764 | ) |
Inventory | |
| 3,928 | | |
| (13,616 | ) |
Prepaids and other current assets | |
| (20,607 | ) | |
| (138 | ) |
Accounts payable | |
| 846,001 | | |
| (118,561 | ) |
Accrued expenses | |
| 340,317 | | |
| 266,486 | |
Customer deposits | |
| 2,143 | | |
| (12,720 | ) |
Operating lease liability | |
| (16,698 | ) | |
| (13,791 | ) |
Net cash used by operating activities | |
| (1,248,137 | ) | |
| (1,171,895 | ) |
| |
| | | |
| | |
Cash Flows from Investing Activities | |
| | | |
| | |
Additions to property and equipment | |
| (12,067 | ) | |
| — | |
Additions to intangible assets | |
| (1,000 | ) | |
| (49,815 | ) |
Net cash used by investing activities | |
| (13,067 | ) | |
| (49,815 | ) |
| |
| | | |
| | |
Cash Flows from Financing Activities | |
| | | |
| | |
Principal payments on notes payable | |
| (2,724,479 | ) | |
| (86,453 | ) |
Proceeds from notes payable | |
| 159,831 | | |
| — | |
Proceeds from convertible notes, net of fees | |
| 3,828,000 | | |
| 1,087,500 | |
Offering costs paid | |
| (204,407 | ) | |
| (26,549 | ) |
Net cash used in financing activities | |
| 1,058,945 | | |
| 974,498 | |
| |
| | | |
| | |
Net Decrease in Cash and Cash Equivalents | |
| (202,259 | ) | |
| (247,212 | ) |
| |
| | | |
| | |
Cash and Cash Equivalents at Beginning of Period | |
| 253,699 | | |
| 320,858 | |
| |
| | | |
| | |
Cash and Cash Equivalents at End of Period | |
$ | 51,440 | | |
$ | 73,646 | |
Supplemental Disclosure of Non-cash Cash Activities | |
| | | |
| | |
Cash paid for interest | |
$ | 57,202 | | |
$ | 55,550 | |
Cash paid for income taxes | |
| — | | |
| — | |
Supplemental Schedule of Non-cash Investing and Financing Activities | |
| | | |
| | |
Fair value of warrant liabilities of warrants from convertible notes | |
$ | 1,881,257 | | |
$ | 884,118 | |
Fair value of derivative liabilities of conversion feature from convertible notes | |
| 1,860,984 | | |
| 1,075,098 | |
Exhibit 99.2
v3.23.3
Cover
|
Sep. 21, 2023 |
Cover [Abstract] |
|
Document Type |
8-K
|
Amendment Flag |
false
|
Document Period End Date |
Sep. 21, 2023
|
Entity File Number |
001-41775
|
Entity Registrant Name |
Neuraxis,
Inc.
|
Entity Central Index Key |
0001933567
|
Entity Tax Identification Number |
45-5079684
|
Entity Incorporation, State or Country Code |
DE
|
Entity Address, Address Line One |
11550
N. Meridian Street
|
Entity Address, Address Line Two |
Suite 325
|
Entity Address, City or Town |
Carmel
|
Entity Address, State or Province |
IN
|
Entity Address, Postal Zip Code |
46032
|
City Area Code |
(812)
|
Local Phone Number |
689-0791
|
Written Communications |
false
|
Soliciting Material |
false
|
Pre-commencement Tender Offer |
false
|
Pre-commencement Issuer Tender Offer |
false
|
Title of 12(b) Security |
Common
Stock, $0.001 par value
|
Trading Symbol |
NRXS
|
Security Exchange Name |
NYSEAMER
|
Entity Emerging Growth Company |
true
|
Elected Not To Use the Extended Transition Period |
false
|
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 2 such as Street or Suite number
+ References
+ Details
Name: |
dei_EntityAddressAddressLine2 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Section 14a -Number 240 -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
Neuraxis (AMEX:NRXS)
Historical Stock Chart
From Sep 2024 to Oct 2024
Neuraxis (AMEX:NRXS)
Historical Stock Chart
From Oct 2023 to Oct 2024